Hayward, California-based Arcus Biosciences Inc, an immuno-oncology company, has secured $70 million in funding. The investors included Taiho Ventures, GV, Invus, DROIA Oncology Ventures, Stanford University, The Column Group, Foresite Capital, Novartis and Celgene.

Source: Press Release